Pamrevlumab

Drug Profile

Pamrevlumab

Alternative Names: Anti-CTGF antibody; FG-3019

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator FibroGen
  • Class Antifibrotics; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Connective tissue growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Duchenne muscular dystrophy; Hepatic fibrosis; Idiopathic pulmonary fibrosis; Pancreatic cancer
  • Phase I Glomerulonephritis
  • Preclinical Glioblastoma
  • Discontinued Diabetic cardiomyopathy; Diabetic nephropathies; Diabetic neuropathies

Most Recent Events

  • 12 Aug 2016 FibroGen terminates phase II trial in Hepatic fibrosis in Hong Kong (NCT01217632)
  • 08 Aug 2016 FibroGen completes enrolment in the main study portion of a phase II trial in Idiopathic pulmonary fibrosis in USA, Australia, Bulgaria, Canada, India, New Zealand and South Africa
  • 01 Aug 2016 Jonsson Comprehensive Cancer Center initiates a compassionate single subject clinical trial for Pancreatic cancer (Inoperable/Unresectable, Late-stage disease, Combination therapy) in USA (IV) (NCT02851381)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top